A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin α10β1-selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers
Latest Information Update: 07 May 2025
At a glance
- Drugs Stem cell therapy-Xintela (Primary)
- Indications Leg ulcer; Varicose ulcer
- Focus Adverse reactions
- Sponsors Xintela
Most Recent Events
- 15 Apr 2025 Planned number of patients changed from 12 to 6.
- 15 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Oct 2025.
- 15 Apr 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Oct 2025.